The NATINATI Study: A single intervention to compare the effects of hazelnut consumption on the acceptance and cardiovascular disease risk factors among Maori and European participants.

Not Applicable

Recruiting

• Conditions: Risk factors for cardiovascular disease; Diet and Nutrition - Other diet and nutrition disorders; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12611000230954
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

The inclusion criteria are Maori and European males and females aged between 18 and 40 years of age. They should be in good health.

Exclusion Criteria

The exclusion criteria are smokers. Pregnant or breastfeeding women. People who have asthma, food allergies or food aversions to nuts. People who have familial or secondary hyperlipidaemia or major chronic diseases such as cancer, heart disease or diabetes. People who are taking medication known to affect blood lipid levels.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood lipids and lipoproteins, apolipoproteins. Plasma total cholesterol, HDL-cholesterol and triglyceride concentrations will be measured by enzymatic methods using a Cobas Mira Plus analyser. Plasma LDL-cholesterol concentration will be calculated using the Friedewald formula. Apolipoproteins A1 and B100 concentrations will be determined by immunotubidity using commercial kits from Roche Diagnostics.[At baseline and at 4 weeks after intervention commencement.]

Secondary Outcome Measures

Name	Time	Method
Plasma hs-CRP will be measured by using a Cobas Mira Plus Analyser.[At baseline and at 4 weeks after intervention commencement.];Blood glucose and insulin. Plasma glucose will be measured by using a Cobas Mira Plus Analyser. Plasma insulin will be measured by using Elecsys 2010.[At baseline and at 4 weeks after intervention commencement.];Blood pressure will be measured in triplicate using an Omron pressure monitor (Model HEM-907).[At baseline and at 4 weeks after intervention commencement.];Body composition. This will be measured by using a bioelectrical impedance analysis.[At baseline and at 4 weeks after intervention commencement.];Acceptance for hazelnuts. This will be determined by using a 150mm visual analogue scale.[At baseline, at 4 weeks after intervention commencement and daily during the exposure period.]